A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study
PHASE3CompletedINTERVENTIONAL
Enrollment
26
Participants
Timeline
Start Date
July 2, 2016
Primary Completion Date
April 28, 2017
Study Completion Date
April 28, 2017
Conditions
Primary Open Angle Glaucoma or Ocular Hypertension
Interventions
DRUG
DE-117 ophthalmic solution
DRUG
Latanoprost ophthalmic solution 0.005%
Trial Locations (1)
Unknown
Tokyo
All Listed Sponsors
lead
Santen Pharmaceutical Co., Ltd.
INDUSTRY
NCT02822742 - A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study | Biotech Hunter | Biotech Hunter